期刊
LANCET GASTROENTEROLOGY & HEPATOLOGY
卷 6, 期 1, 页码 57-64出版社
ELSEVIER INC
DOI: 10.1016/S2468-1253(20)30213-2
关键词
-
Fatty liver disease associated with metabolic dysfunction is a global health problem, particularly prevalent in the Middle East and North Africa. The current nomenclature and diagnostic criteria for the disease have raised concerns among experts, leading to a proposal to rename it as metabolic-associated fatty liver disease (MAFLD) and diagnose it by positive criteria. Recommendations are being made to work with authorities in the region to implement these changes and improve healthcare for patients.
With the increasing prevalence of obesity and type 2 diabetes, fatty liver disease associated with metabolic dysfunction is a global health problem, especially because it is one of the earliest consequences of obesity and it precedes diabetes development. Fatty liver disease associated with metabolic dysfunction is of particular concern in the Middle East and north Africa, where its prevalence is greater than that in the rest of the world. Despite the magnitude of the problem, no regional guidelines have been developed to address this disease. This Review describes suggestions of redefining fatty liver disease associated with metabolic dysfunction, including its terminology and criteria for diagnosis. Experts have raised serious concerns on the current nomenclature, which labels the disease as non-alcoholic fatty liver disease (NAFLD), and its diagnostic criteria. The panel reached a consensus that the disease should be renamed as metabolic-associated fatty liver disease (MAFLD) and that the disease should be diagnosed by positive criteria. The aim is now to work with authorities across the region to implement these proposed changes and reflect them in health-care policy and to improve health care for patients in this region.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据